Real-time financial, economic, and global news with market-focused context and analysis.
Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.
Unity Software's stock jumped 17% after the company reported a stronger-than-expected second quarter, with revenue and adjusted-profit metrics beating analyst estimates and management issuing a bullish revenue and adjusted EBITDA outlook for the third quarter. Strategic revenue, excluding certain business lines, showed particularly strong growth, w…
Constellation Energy Corp. stock surged 4.4% in pre-open trading after the company posted a second-quarter adjusted operating earnings beat and raised its fiscal 2026 outlook. Management also announced two board-level moves in the days ahead of the earnings release, reinforcing investor confidence despite recent analyst target cuts.
Insmed shares jumped 19.2% in pre-market trading after the company reported second-quarter 2026 results that outpaced analyst expectations on both revenue and EPS. Total revenue reached $425.5 million, led by Brinsupri sales of $309.2 million, and the company posted a near-breakeven net loss of $0.06 per share. Management raised full-year Brinsupri…
Fiserv's stock tumbled sharply in pre-market trading after the payments processor reported second-quarter results that missed expectations and issued weaker full-year guidance. Adjusted revenue and EPS declined year-over-year, management trimmed organic revenue and adjusted EPS forecasts for 2026, and investor concern has been amplified by recent l…
Hyliion Holdings will supply NAVSEA Philadelphia with two multi-megawatt KARNO Power Modules under a $41.7 million Office of Naval Research contract. The delivery expands naval testing and deployment of the company's modular architecture and pushes cumulative ONR support beyond $58 million, covering validation, testing, at-sea trials and now multi-…
Arcutis Biotherapeutics disclosed a routine equity divestment by its Executive Vice President and Chief Medical Officer, executed to cover tax withholding on vested restricted stock units. The transaction coincides with a period of accelerated financial performance, as the company recently reported a significant second-quarter revenue beat and offi…
Innoviva is facing genuine royalty roll-off concerns, but the stock's current valuation - roughly $1.52B market cap, P/E ~3, EV/EBITDA ~5.8 and an implied FCF yield near 12% - already factors in a dramatic earnings collapse. That makes a tactical long with defined risk-management attractive. This trade plan lays out entry, stop and layered targets …
NRG's recent LS Power acquisition (13 GW added) and raised FY26 guidance materially enlarge its generation footprint and optionality into data-center power. The numbers show upgraded EBITDA and FCF guidance, but the balance sheet and prior quarterly noise argue for an active, risk-managed long. This trade idea targets $150 with a $110 stop over a 1…
CT3 says its recently introduced Storage Contracts enabled rapid expansion of connected capacity to absorb higher volumes of user data after the rollout of an automatic backup service. To avoid excess idle capacity, the company will limit the sale of new contracts to the amount of storage that can be productively used, with some larger-capacity con…
BioVie Inc. announced positive topline results from its Phase 2 SUNRISE-PD trial evaluating bezisterim in early-stage Parkinson's disease patients. The drug met its primary and secondary endpoints, showing significant improvements on motor and non-motor symptoms, beneficial effects on neuroinflammation biomarkers, and a broadly favorable proteomic …
Abeona Therapeutics Inc. will hold a conference call on August 13, 2026, to discuss its second quarter financial results and provide a corporate update. The company is a commercial-stage biopharmaceutical firm focused on developing cell and gene therapies for serious diseases, including its FDA-approved ZEVASKYN therapy for recessive dystrophic epi…
Parker Hannifin Corporation announced record financial results for the fiscal 2026 fourth quarter and full year, with significant increases in sales, net income, and earnings per share. The company delivered operational excellence marked by improved segment operating margins and strong organic sales growth across all segments. Strategic acquisition…
Collegium Pharmaceutical announced its second quarter 2026 financial results, highlighting a 6% year-over-year increase in net revenues to $199.9 million. Growth was driven by a 41% increase in JORNAY PM revenue and the recent acquisition of AZSTARYS, which contributed $12.9 million in partial quarter sales. While the pain portfolio revenues declin…
EuroDry Ltd., a drybulk vessel operator listed on NASDAQ, announced strong financial results for Q2 and H1 2026, including a net income of $6.6 million for Q2 versus a net loss of $3.1 million a year earlier. Total net revenues grew 57% in Q2 to $17.7 million, driven by a 95.6% increase in average time charter equivalent rates. Adjusted EBITDA surg…
MACOM Technology Solutions Holdings, Inc. announced robust financial results for its fiscal third quarter ended July 3, 2026, reporting a 35.8% year-over-year increase in revenue to $342.2 million and a significant rise in net income to $100.7 million ($1.28 per diluted share), driven by strong demand in telecommunications, industrial, defense, and…
Genie Energy Ltd. announced its second quarter 2026 financial results, highlighting a decrease in revenue but strong growth in gross profit, income from operations, net income, and earnings per share. The company experienced improved gross margins driven by normalized wholesale energy market conditions and focused customer acquisition in high-value…
Electra Battery Materials Corporation welcomed the U.S. Department of Commerce's new rule restricting exports of battery black mass, aiming to keep critical minerals within the U.S. This aligns with Electra's strategy to develop domestic refining capacity for nickel and recycled battery materials, addressing supply chain and national security conce…
Cerenome, Inc., through its subsidiary CNSide Diagnostics, has selected XiFin Empower RCM to provide AI-driven revenue cycle management and clearinghouse services for its CNSide cerebrospinal fluid assay platform. This partnership is designed to streamline billing processes, including addressing backlog claims, and enable scalable test volume growt…
Cronos Group reported its second quarter 2026 results with a 51% year-over-year increase in net revenue on a constant-currency basis, driven by record revenues in Canada, Israel, and international markets like Germany. The company achieved record gross profit and Adjusted EBITDA, significantly improved net income, and reduced share count through re…
Lexicon Pharmaceuticals completed enrollment for its pivotal Phase 3 SONATA-HCM study investigating sotagliflozin for hypertrophic cardiomyopathy, expects topline results in Q1 2027, and is nearing completion of NDA resubmission activities for ZYNQUISTA® in type 1 diabetes. The company also reported a net loss for Q2 2026 driven by increased R&D sp…
Kelly Services, a specialty talent solutions provider listed on Nasdaq, announced its second-quarter 2026 results showing a 5.8% year-over-year revenue decline with improving trends across its Enterprise Talent Management (ETM) and Science, Engineering & Technology (SET) segments. Operating earnings were $16.1 million with adjusted EBITDA margin im…
Compass Therapeutics reported second quarter 2026 financial results and provided corporate updates, highlighting positive tovecimig Phase 2/3 data and expected FDA feedback this quarter. The company is advancing clinical trials for several bispecific antibody candidates targeting cancers, including expansions for CTX-8371 and initiation of CTX-471 …
SAB Biotherapeutics reports Q2 2026 financial results highlighting progress in their SAB-142 immunotherapy for type 1 diabetes. The SAFEGUARD Phase 2b trial is on track with over 60 clinical sites activated and enrollment expected to complete by Q4 2026, with topline data anticipated in the second half of 2027. The company also secured a grant for …
Nayax Ltd., a Nasdaq-listed global commerce enablement and payments platform, has filed an application with the Connecticut Department of Banking to establish Nayax America Bank Inc., a non-depository innovation bank headquartered in Connecticut. The new bank, owned by Nayax USA Holdings, aims to offer embedded financial services such as corporate …
InflaRx N.V. announced its second quarter 2026 financial results alongside key clinical and strategic updates. The company is advancing its oral C5aR inhibitor, izicopan, targeting ANCA-associated vasculitis (AAV) and select renal diseases, with Phase 2 clinical preparations ongoing. InflaRx is exploring regulatory strategies following the European…
